J 2024

Low CD46 expression on activated CD4+ T cells predict improved Th1 cell reactivity to calcitriol in majority of patients with allergic eosinophilic asthma and healthy donors

ŠTÍCHOVÁ, Julie; Peter SLANINA; Zita CHOVANCOVÁ; Jan BAROŠ; Marek LITZMAN et al.

Základní údaje

Originální název

Low CD46 expression on activated CD4+ T cells predict improved Th1 cell reactivity to calcitriol in majority of patients with allergic eosinophilic asthma and healthy donors

Autoři

Vydání

Frontiers in Allergy, Lausanne, Frontiers, 2024, 2673-6101

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30102 Immunology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 3.100

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/24:00137196

Organizační jednotka

Lékařská fakulta

UT WoS

001330400600001

EID Scopus

2-s2.0-85205689421

Klíčová slova česky

alergické eosinofilní astma; kalcitriol; CD46, IFN-γ; IL-10

Klíčová slova anglicky

allergic eosinophilic asthma; calcitriol; CD46; IFN-γ; IL-10

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 4. 4. 2025 12:58, Mgr. Tereza Miškechová

Anotace

V originále

Background Previous research showed that the intracellular complement system, with CD46 as its central molecule, regulates the Th1 response associated with IFN-gamma production and transition to a type 1 regulatory response (Tr1) characterized by IL-10 production. This transition can be influenced by a vitamin D (calcitriol), favouring a shift towards Tr1 cells and increased IL-10 production, as described in some autoimmune diseases. Objective It is unknown whether calcitriol modulates CD46-induced Th1 response towards regulatory type 1 T cells (Tr1) in allergic eosinophilic asthma and its value in relation to reducing inflammatory response. Methods CD4(+) T cells from 58 patients with allergic eosinophilic asthma (AEA) and 49 healthy donors (HDs) were stimulated with alpha CD3/alpha CD46/IL-2 or alpha CD3/alpha CD46/IL-2/Calcitriol in vitro for 60 h and analyzed by flow cytometry. IFN-gamma and IL-10 levels in cell culture supernatants were measured using ELISA. Results CD4(+) T cells from patients with AEA demonstrated elevated CD46 expression in both the non-activated state and under stimulation conditions with alpha CD3/alpha CD46/IL-2 or alpha CD3/alpha CD46/IL-2/Calcitriol. Moreover, CD46 expression in AEA patients fluctuated with the pollen season, showing a significant increase during period of low pollen exposure. Calcitriol further induced CD4(+)Tr1 cells from in vitro generated CD4(+)Th1 cells in both HDs and AEA patients. However, in both cohorts were individuals (HDs: 35/49, AEA: 40/58) who responded to calcitriol with a more pronounced regulatory response. The calcitriol-induced regulatory effect manifested by a stronger surface decrease of CD46 on activated CD4+ T cells (by 40% in HDs and by 26% in AEA), accompanied by a significant inhibition of IFN-gamma and increased IL-10 production (by 31% in HDs and by 85% in AEA). These individuals were termed as the CD46D group. Contrary to this, calcitriol induced an increase in CD46 expression at the CD4(+) T cell surface in a minor group of HDs (14/49), and AEA patients (18/58), who were termed as the CD46I group. In CD46I group, CD4(+) T cells produced less IFN-gamma in comparison with CD46D group (by 33% in HDs and by 43% in AEA) and were unable to upregulate IL-10 production following stimulation with alpha CD3/alpha CD46/IL-2/Calcitriol. Conclusion Our results suggest the potential existence of a key for stratifying individuals suitable for calcitriol treatment in the context of low serum vitamin D levels. After validation in clinical studies, this key could be used as an adjunctive therapy not only for patients with allergic eosinophilic asthma, but also for other diseases.

Návaznosti

MUNI/A/1566/2023, interní kód MU
Název: Patogeneze imunopatologických chorob
Investor: Masarykova univerzita, Patogeneze imunopatologických chorob
NU20-05-00146, projekt VaV
Název: Změny intracelulárního komplementu u pacientů s alergickým eozinofilním astmatem
Investor: Ministerstvo zdravotnictví ČR, Změny intracelulárního komplementu u pacientů s alergickým eozinofilním astmatem, Podprogram 1 - standardní